Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: Hepatitis C virus (HCV) is associated with B-cell disorders, including mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Early diagnosis of B-NHL in HCV-infected patients, in particular those with MC vasculitis, is critical to determine the optimal therapeutic management.
Aim: We hypothesized that combination of serum biomarkers could be used to identify B-NHL associated with MC in patients with chronic HCV infection.
Methods: 155 HCV infected patients have been included [median age 62 (31-85) years, M/F 70/85], with and without MC and/or B-NHL [57 patients without MC, 17 patients with asymptomatic MC, 62 patients with MC vasculitis, and 19 patients with MC vasculitis and B-NHL]. We measured serum levels of 8 markers previously described to be increased in patients with B-NHL i.e. soluble CD22, soluble CD27, soluble IL-2Ra, soluble CD137, free-light chains of immunoglobulins, heavy chains of immunoglobulins, gammaglobulins and C4 complement fraction. We used a multiparametric analysis in order to determine a signature that identifies patients with overt B-NHL associated with MC in chronic HCV infection.
Results: Serum levels were significantly different between patients without MC, patients with asymptomatic MC, patients with MC vasculitis and those with MC vasculitis and B-NHL: soluble CD22 (6.7 vs. 11.9 vs. 20.8 vs. 36.4 ng/ml, P<0.0001), soluble CD27 (71.9 vs. 75.7 vs. 122.9 vs. 263.9 U/ml, P<0.0001), soluble IL-2Ra (877 vs. 1035 vs. 2206 vs. 4044 pg/ml, P<0.0001), soluble CD137 (296 vs. 426 vs. 539 vs. 763 pg/ml, P<0.0001), free-light chains of immunoglobulins (ratio k/l 1.13 vs. 1.08 vs. 1.79 vs. 3.01, P<0.0001), heavy chains of immunoglobulins (ratio IgMk/IgMl 1.90 vs. 1.85 vs. 4.85 vs. 31.3, P<0.0001), gammaglobulins (14.1 vs. 17.0 vs. 12.1 vs. 6.0 g/l, P<0.0001) and C4 complement fraction (0.23 vs. 0.16 vs. 0.07 vs. 0.04 g/l, P<0.0001).
Using multiparametric analysis, we identified a signature involving soluble CD27, soluble IL-2Rα, gammaglobulins and C4 levels associated with the presence of overt B-NHL in HCV-infected patients. This signature had a sensitivity of 100%, a specificity of 63%, and positive and negative predictive values of 94 and 100% for discriminating patients with overt B-NHL and those without B-NHL.
Conclusion: Overall, our data indicate that serum biomarkers signature allows identifying patients presenting with overt B-NHL associated with mixed cryoglobulinemia vasculitis in chronic HCV infection, and requiring invasive explorations in order to demonstrate the presence of malignant lymphoma.
Disclosure:
B. Terrier,
None;
W. Chaara,
None;
G. Geri,
None;
D. Saadoun,
None;
M. Rosenzwajg Sr.,
None;
D. Sene Sr.,
None;
A. Six,
None;
D. Klatzmann Sr.,
None;
P. Cacoub Sr.,
None.
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-biomarkers-signature-identifies-patients-with-overt-b-cell-non-hodgkin-lymphoma-associated-with-mixed-cryoglobulinemia-in-chronic-hcv-infection/